Compugen Analyst Ratings
Compugen Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/23/2023 | 223.89% | Truist Securities | → $4 | Reiterates | Buy → Buy |
| 08/07/2023 | 952.63% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 06/06/2023 | 952.63% | EF Hutton | → $13 | Reiterates | → Buy |
| 05/26/2023 | 952.63% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 05/24/2023 | 952.63% | EF Hutton | → $13 | Reiterates | Buy → Buy |
| 05/16/2023 | 466.8% | Oppenheimer | $8 → $7 | Maintains | Outperform |
| 02/28/2023 | 547.77% | Oppenheimer | → $8 | Reiterates | → Outperform |
| 02/08/2023 | -59.51% | Jefferies | → $0.5 | Downgrades | Hold → Underperform |
| 01/05/2023 | 952.63% | EF Hutton | → $13 | Initiates Coverage On | → Buy |
| 11/15/2022 | 547.77% | Oppenheimer | $12 → $8 | Maintains | Outperform |
| 08/23/2022 | 223.89% | Truist Securities | $14 → $4 | Maintains | Buy |
| 08/08/2022 | 223.89% | JMP Securities | $8 → $4 | Maintains | Market Outperform |
| 08/08/2022 | 871.66% | Oppenheimer | $14 → $12 | Maintains | Outperform |
| 08/05/2022 | 61.94% | Jefferies | → $2 | Downgrades | Buy → Hold |
| 02/25/2022 | 1033.6% | Oppenheimer | $17 → $14 | Maintains | Outperform |
| 02/25/2022 | 628.74% | SVB Leerink | $16 → $9 | Maintains | Outperform |
| 04/06/2021 | 1195.55% | SVB Leerink | $19 → $16 | Maintains | Outperform |
| 08/19/2020 | 1438.46% | SVB Leerink | $15 → $19 | Maintains | Outperform |
| 05/13/2020 | 1438.46% | Stifel | → $19 | Initiates Coverage On | → Buy |
| 05/07/2020 | 1114.57% | SVB Leerink | → $15 | Initiates Coverage On | → Outperform |
| 04/22/2020 | 2167.21% | Roth Capital | → $28 | Initiates Coverage On | → Buy |
| 03/24/2020 | 1195.55% | SunTrust Robinson Humphrey | → $16 | Initiates Coverage On | → Buy |
| 02/21/2020 | 952.63% | Cantor Fitzgerald | $10 → $13 | Reiterates | → Overweight |
| 01/16/2020 | 709.72% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析师事务所 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/23/2023 | 223.89% | Truist 证券 | → 4 美元 | 重申 | 购买 → 购买 |
| 08/07/2023 | 952.63% | EF Hutton | → 13 美元 | 重申 | 购买 → 购买 |
| 06/06/2023 | 952.63% | EF Hutton | → 13 美元 | 重申 | → 购买 |
| 05/26/2023 | 952.63% | EF Hutton | → 13 美元 | 重申 | 购买 → 购买 |
| 05/24/2023 | 952.63% | EF Hutton | → 13 美元 | 重申 | 购买 → 购买 |
| 05/16/2023 | 466.8% | 奥本海默 | 8 美元 → 7 美元 | 维护 | 跑赢大盘 |
| 02/28/2023 | 547.77% | 奥本海默 | → 8 美元 | 重申 | → 跑赢大盘 |
| 02/08/2023 | -59.51% | 杰富瑞集团 | → 0.5 美元 | 降级 | 持有 → 表现不佳 |
| 01/05/2023 | 952.63% | EF Hutton | → 13 美元 | 启动覆盖范围开启 | → 购买 |
| 11/15/2022 | 547.77% | 奥本海默 | 12 美元 → 8 美元 | 维护 | 跑赢大盘 |
| 2022 年 8 月 23 日 | 223.89% | Truist 证券 | 14 美元 → 4 美元 | 维护 | 购买 |
| 08/08/2022 | 223.89% | JMP 证券 | 8 美元 → 4 美元 | 维护 | 市场表现跑赢大盘 |
| 08/08/2022 | 871.66% | 奥本海默 | 14 美元 → 12 美元 | 维护 | 跑赢大盘 |
| 08/05/2022 | 61.94% | 杰富瑞集团 | → 2 美元 | 降级 | 买入 → 持有 |
| 2022 年 2 月 25 日 | 1033.6% | 奥本海默 | 17 美元 → 14 美元 | 维护 | 跑赢大盘 |
| 2022 年 2 月 25 日 | 628.74% | SVB Leerink | 16 美元 → 9 美元 | 维护 | 跑赢大盘 |
| 04/06/2021 | 1195.55% | SVB Leerink | 19 美元 → 16 美元 | 维护 | 跑赢大盘 |
| 2020 年 8 月 19 日 | 1438.46% | SVB Leerink | 15 美元 → 19 美元 | 维护 | 跑赢大盘 |
| 05/13/2020 | 1438.46% | Stifel | → 19 美元 | 启动覆盖范围开启 | → 购买 |
| 05/07/2020 | 1114.57% | SVB Leerink | → 15 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2020 年 4 月 22 日 | 2167.21% | 罗斯资本 | → 28 美元 | 启动覆盖范围开启 | → 购买 |
| 2020 年 3 月 24 日 | 1195.55% | SunTrust 罗宾逊·汉弗莱 | → 16 美元 | 启动覆盖范围开启 | → 购买 |
| 02/21/2020 | 952.63% | 坎托·菲茨杰拉德 | 10 美元 → 13 美元 | 重申 | → 超重 |
| 2020 年 1 月 16 日 | 709.72% | 坎托·菲茨杰拉德 | → 10 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Compugen (CGEN)?
Compugen（CGEN）的目标价格是多少？
The latest price target for Compugen (NASDAQ: CGEN) was reported by Truist Securities on August 23, 2023. The analyst firm set a price target for $4.00 expecting CGEN to rise to within 12 months (a possible 223.89% upside). 10 analyst firms have reported ratings in the last year.
Truist Securities于2023年8月23日公布了Compugen（纳斯达克股票代码：CGEN）的最新目标股价。该分析公司将目标股价设定为4.00美元，预计CGEN将在12个月内上涨至4.00美元（可能上涨223.89％）。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Compugen (CGEN)?
Compugen（CGEN）的最新分析师评级是多少？
The latest analyst rating for Compugen (NASDAQ: CGEN) was provided by Truist Securities, and Compugen reiterated their buy rating.
Compugen（纳斯达克股票代码：CGEN）的最新分析师评级由Truist Securities提供，Compugen重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Compugen (CGEN)?
Compugen（CGEN）的下一个分析师评级何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Compugen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Compugen was filed on August 23, 2023 so you should expect the next rating to be made available sometime around August 23, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Compugen的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应获得4个评级。Compugen的最后一次评级是在2023年8月23日提交的，因此您应该预计下一个评级将在2024年8月23日左右公布。
Is the Analyst Rating Compugen (CGEN) correct?
分析师评级 Compugen (CGEN) 是否正确？
While ratings are subjective and will change, the latest Compugen (CGEN) rating was a reiterated with a price target of $0.00 to $4.00. The current price Compugen (CGEN) is trading at is $1.24, which is within the analyst's predicted range.
尽管评级是主观的，而且会发生变化，但最新的Compugen（CGEN）评级得到了重申，目标股价为0.00美元至4.00美元。Compugen（CGEN）目前的交易价格为1.24美元，在分析师的预测区间内。